Alternative Dosing And Prevention of Transfusions (ADAPT): A Prospective Study to Reduce Transfusion Requirements for Children With Sickle Cell Anemia Using Pharmacokinetics-based Hydroxyurea Dosing

About the study

ADAPT is a prospective cohort study at Jinja Regional Referral Hospital (JRRH) primarily to assess the effect of hydroxyurea on blood transfusion utilization and secondarily to determine the feasibility of PK-guided hydroxyurea dosing.

Study point of contact

Russell Ware, MD, PhD
(513) 803-1108
[email protected]
Teresa Latham, M.A., LPCC-S
(513) 803-7922
[email protected]


12 Months - 10 Years


Early Phase 1

Study type






participation requirements

Patients with documented HbSS disease
Age: ≥ 12 months and ≤ 10 years of age, at the time of enrollment
Parent or guardian willing and able to provide informed consent
Able to comply with all study related treatments, evaluations, and follow-up

participation restrictions

Current hydroxyurea treatment (or within the past 6 months)
Regular blood transfusions (6 or more within the past 12 months)
Transfusion within the last 30 days (temporary exclusion)
Known malignancy or other known chronic illnesses including but not limited to active tuberculosis, renal disease
Current participation in other therapeutic clinical trials, or within 6 months of prior disease-modifying treatments

Last updated 2022-12-14